For example, adding tremelimumab to anti-PDL1 did not improve the clinical outcome of patients with aggressive cancers such as small cell lung carcinoma, extensive disease (SCLC-ED), in which chemotherapy is still a mainstay treatment to controlling disease and palliating symptoms [43]. Here, CD274 is linked to cancer.